RT Journal Article
SR Electronic
T1 Use of multitarget tyrosine kinase inhibitors to attenuate platelet-derived growth factor signalling in lung disease
JF European Respiratory Review
JO EUROPEAN RESPIRATORY REVIEW
FD European Respiratory Society
SP 170061
DO 10.1183/16000617.0061-2017
VO 26
IS 146
A1 Rana Kanaan
A1 Charlie Strange
YR 2017
UL http://err.ersjournals.com/content/26/146/170061.abstract
AB Platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) play a fundamental role in the embryonic development of the lung. Aberrant PDGF signalling has been documented convincingly in a large variety of pulmonary diseases, including idiopathic pulmonary arterial hypertension, lung cancer and lung fibrosis. Targeting PDGF signalling has been proven to be effective in these diseases. In clinical practice, the most effective way to block PDGF signalling is to inhibit the activity of the intracellular PDGFR kinases. Although the mechanism of action of such drugs is not specific for PDGF signalling, the medications have a broad therapeutic index that allows clinical use. The safety profile and therapeutic opportunities of these and future medications that target PDGFs and PDGFRs are reviewed.An increasing role for PDGF signalling inhibitors in clinical trials for the treatment of various pulmonary diseases http://ow.ly/buaI30f9HcN